WallStreetZenWallStreetZen

NASDAQ: VTGN
Vistagen Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for VTGN

Based on 1 analyst offering 12 month price targets for Vistagen Therapeutics Inc.
Min Forecast
$15.00+269.46%
Avg Forecast
$15.00+269.46%
Max Forecast
$15.00+269.46%

Should I buy or sell VTGN stock?

Based on 1 analyst offering ratings for Vistagen Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VTGN stock forecasts and price targets.

VTGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-12-07

1 of 1

Forecast return on equity

Is VTGN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.79%

Forecast return on assets

Is VTGN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

VTGN revenue forecast

What is VTGN's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$405.0k-61.14%
Avg 2 year Forecast
$5.0M+379.71%
VTGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VTGN revenue growth forecast

How is VTGN forecast to perform vs Biotechnology companies and vs the US market?
Company
109.58%
Industry
35.65%
Market
10.58%
VTGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VTGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VTGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VTGN$4.06$15.00+269.46%Strong Buy
DMAC$2.85$7.00+145.61%Buy
ADAG$2.53N/AN/A
IMUX$1.25$10.00+700.00%Strong Buy
CLRB$2.96$20.00+575.68%Strong Buy

Vistagen Therapeutics Stock Forecast FAQ

Is Vistagen Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VTGN) stock is to Strong Buy VTGN stock.

Out of 1 analyst, 1 (100%) are recommending VTGN as a Strong Buy, 0 (0%) are recommending VTGN as a Buy, 0 (0%) are recommending VTGN as a Hold, 0 (0%) are recommending VTGN as a Sell, and 0 (0%) are recommending VTGN as a Strong Sell.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.

What is VTGN's revenue growth forecast for 2025-2027?

(NASDAQ: VTGN) Vistagen Therapeutics's forecast annual revenue growth rate of 109.58% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.58%.

Vistagen Therapeutics's revenue in 2024 is $1,042,300.On average, 2 Wall Street analysts forecast VTGN's revenue for 2025 to be $10,945,210, with the lowest VTGN revenue forecast at $10,810,084, and the highest VTGN revenue forecast at $11,080,336.

In 2027, VTGN is forecast to generate $135,126,045 in revenue, with the lowest revenue forecast at $135,126,045 and the highest revenue forecast at $135,126,045.

What is VTGN's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: VTGN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is VTGN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VTGN price target, the average VTGN price target is $15.00, with the highest VTGN stock price forecast at $15.00 and the lowest VTGN stock price forecast at $15.00.

The Wall Street analyst predicted that Vistagen Therapeutics's share price could reach $15.00 by Dec 7, 2024. The average Vistagen Therapeutics stock price prediction forecasts a potential upside of 269.46% from the current VTGN share price of $4.06.

What is VTGN's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: VTGN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.